抑制H3K27脱甲基酶降低CREB-CREBBP,克服复发性急性淋巴细胞白血病中的抵抗
Juan Lazaro-Navarro1,2, Clara Alcon3,4, Mathurin Dorel5
1Department of Pediatric Oncology/Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Cancer medicine
|January 10, 2025
概括
这项研究表明,用GSK-J4抑制H3K27脱甲基酶可以克服急性淋巴细胞白血病 (ALL) 的耐药性. 高CREBBP表达预测了对GSK-J4的敏感性,建议将其作为治疗的生物标志物.
科学领域:
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
- 血液学 血液学 血液学
背景情况:
- CREB结合蛋白 (CREBBP) 是一种关键的表观遗传调节剂,与复发性急性淋巴细胞白血病 (ALL) 有关.
- 向表观遗传信号提供了一种新的策略来打击ALL的耐药性.
- 一种H3K27基因组脱甲基酶抑制剂GSK-J4在临床前癌症模型中显示出抗瘤作用.
研究的目的:
- 研究GSK-J4在ALL中的治疗潜力.
- 描述GSK-J4抗白血病作用背后的分子机制.
- 为了确定生物标志物来预测对GSK-J4治疗的反应.
主要方法:
- 使用了药物反应概况,CRISPR-Dropout查,BH3概况和免疫血栓.
- 对ALL细胞系和来自患者的样本进行了实验.
- 分析的重点是GSK-J4对CREB,CREBBP和与亡相关的蛋白质的影响.
主要成果:
- 发现GSK-J4可以降低B细胞前体ALL (BCP-ALL) 中的CREB和CREBBP.
- 高CREBBP表达与对GSK-J4的敏感性增加和对德克萨米他的敏感性降低相关.
- 治疗GSK-J4诱导了对Bcl-2和Bcl-XL的依赖,导致了亡.
结论:
- 抑制H3K27脱甲基酶代表了耐火性ALL的有前途的治疗策略.
- CREBBP作为一种潜在的生物标志物,可以预测患者对GSK-J4.4的反应.
- 与GSK-J4,venetoclax和navitoclax的联合治疗显示出协同效应.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Chromatin Modification in iPS Cells
1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K


